Pediatric Neuroblastoma Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), and by End-User (Hospitals, Specialty Clinics and Others), by region, and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationPediatric Neuroblastoma Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), and by End-User (Hospitals, Specialty Clinics and Others), by region, and Competition
| Forecast Period | 2024-2028 |
| Market Size (2022) | 1.40 billion |
| CAGR (2024-2028) | 8.58% |
| Fastest Growing Segment | Chemotherapy |
| Largest Market | North America |
Market Overview
Global Pediatric Neuroblastoma Treatment Market has valued at USD 1.40 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.58% through 2028. Pediatric Neuroblastoma is a type of cancer that primarily affects young children, usually occurring in infants and toddlers but occasionally in older children. It arises from immature nerve cells (neuroblasts) that are found in various areas of the body, most commonly in the adrenal glands, which sit on top of the kidneys. However, it can also develop in other parts of the sympathetic nervous system, including the chest, abdomen, and pelvis. The symptoms of neuroblastoma vary depending on the tumor's size, location, and whether it has spread. Common symptoms may include abdominal swelling, pain, a lump or mass, weight loss, loss of appetite, bone pain, irritability, fever, and changes in the eyes (such as drooping eyelids or unequal pupil size). Diagnosis often involves a combination of imaging tests, such as ultrasound, CT scans, and MRI scans, to locate and evaluate the tumor. Biopsy and bone marrow aspiration may also be performed to confirm the diagnosis and determine the tumor's aggressiveness.
An increase in the number of pediatric neuroblastoma cases worldwide has driven the demand for treatments. Factors contributing to this rise may include improved diagnostic techniques and increased awareness leading to early detection. Ongoing research and development efforts have led to the discovery of new treatment modalities, targeted therapies, and innovative drug formulations that offer improved outcomes for pediatric neuroblastoma patients. The pharmaceutical industry and research institutions conduct clinical trials to test new therapies and treatment approaches. The participation of pediatric neuroblastoma patients in these trials provides access to cutting-edge treatments and fosters market growth. Pediatric cancer awareness and advocacy organizations work to raise awareness about neuroblastoma, promote early diagnosis, and provide support for patients and their families. Increased awareness can lead to greater demand for treatments.
Key Market Drivers
Rising Incidence of Pediatric Neuroblastoma
Growing awareness among healthcare providers and the public about the signs and symptoms of pediatric neuroblastoma has led to earlier diagnosis. As more cases are detected at an earlier stage, there is a greater need for timely and effective treatment. Improved diagnostic techniques, such as genetic testing and advanced imaging, have made it easier to identify neuroblastoma cases accurately. This early detection allows for prompt intervention and treatment. The general growth in the global population, including the pediatric population, naturally leads to an increase in the number of neuroblastoma cases. While the exact causes of neuroblastoma remain unclear, some environmental and genetic factors may contribute to its development. As these factors continue to be studied, it may become possible to identify at-risk populations more effectively. The rising incidence of neuroblastoma has prompted increased research into potential treatments. Clinical trials and research efforts are essential in developing new therapies, which, in turn, drive the demand for Pediatric Neuroblastoma Treatment. The development of more effective and less toxic treatment options has improved the chances of successful outcomes for neuroblastoma patients. This has increased the demand for these treatments as they become more accessible. Advances in supportive care for pediatric cancer patients have improved overall treatment experiences and outcomes. As the quality of care continues to improve, more families seek treatment for their children. Improved access to healthcare services in various regions around the world means that more children with neuroblastoma are receiving appropriate treatment. This factor will help in the development of the Global Pediatric Neuroblastoma Treatment Market.
Advancements in Medical Research
Researchers have made substantial progress in understanding the genetic and molecular characteristics of neuroblastoma tumors. This has led to the identification of specific genetic mutations and alterations associated with the disease. This information is crucial for developing targeted therapies and personalized treatment approaches. Advances in research have led to the development of targeted therapies that aim to specifically inhibit the activity of genes or proteins involved in neuroblastoma growth. For example, drugs targeting the ALK gene mutation have shown promise in treating neuroblastoma patients with this specific genetic alteration. Immunotherapy, such as chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibitors, has emerged as a groundbreaking approach in pediatric neuroblastoma treatment. These therapies harness the body's immune system to recognize and attack cancer cells. Researchers are actively identifying biomarkers, which are specific molecules or indicators associated with the disease. Biomarkers can be used for early detection, monitoring treatment response, and predicting outcomes in neuroblastoma patients.
Liquid biopsy techniques are being developed to detect tumor-specific DNA or RNA in blood or other bodily fluids. This non-invasive approach may provide valuable information about the presence of neuroblastoma and its genetic characteristics. Ongoing clinical trials are testing new treatment modalities, drug combinations, and therapeutic approaches. These trials offer pediatric neuroblastoma patients access to cutting-edge treatments and help advance the field. Refinements in radiation therapy techniques, including proton therapy and stereotactic radiosurgery, are reducing the potential long-term side effects of radiation while effectively targeting neuroblastoma tumors. Research in supportive care focuses on improving the quality of life for pediatric neuroblastoma patients by managing treatment-related side effects, pain, and psychosocial needs. Collaboration among research institutions, healthcare providers, and pharmaceutical companies on a global scale has accelerated progress in pediatric neuroblastoma research. International collaborations allow for larger patient populations and more extensive data sharing. Research is also focused on long-term survivorship care for pediatric neuroblastoma survivors, addressing late effects of treatment and providing ongoing monitoring and support. This factor will pace up the demand of the Global Pediatric Neuroblastoma Treatment Market.
Rise in Clinical Trials and Drug Development
Clinical trials provide access to novel and experimental treatments that may not be found at through standard care. This attracts pediatric neuroblastoma patients and their families who are seeking the latest and potentially more effective treatment options. The process of drug development involves extensive research aimed at discovering and testing new drugs and treatment modalities. The progression from preclinical studies to clinical trials requires a substantial investment in research and development, which contributes to the availability of new treatment options. Clinical trials are designed to evaluate the safety and effectiveness of new therapies. Positive results from these trials can lead to the approval and commercial availability of these treatments, driving demand for effective pediatric neuroblastoma therapies. Research in pediatric neuroblastoma has advanced our understanding of the genetic and molecular factors that influence the disease. This knowledge has led to the development of targeted therapies tailored to the individual characteristics of a patient's tumor, contributing to improved treatment outcomes.
Clinical trials often explore the effectiveness of combining different treatment approaches, such as chemotherapy with immunotherapy or radiation therapy. These combination therapies may offer synergistic benefits in treating neuroblastoma, further increasing treatment options. Clinical trials are frequently conducted on an international scale, involving multiple research institutions, healthcare providers, and pharmaceutical companies. This collaboration expands the reach of clinical trials and enhances the potential for enrolling a diverse group of patients. Successful completion of clinical trials and the subsequent approval of new drugs or treatment protocols by regulatory agencies (e.g., the FDA in the United States) can lead to their inclusion in treatment guidelines and recommendations, increasing their adoption. Pediatric oncology is a dynamic field, and the continuous pursuit of better treatments for childhood cancers, including neuroblastoma, drives demand for the latest advancements in drug development and clinical research. Advocacy groups and organizations focused on pediatric neuroblastoma often play a crucial role in raising awareness of clinical trials and encouraging patient participation. They help connect patients and families with relevant clinical trials. Clinical trials generate valuable data that contribute to collective knowledge about pediatric neuroblastoma treatment. The sharing of research findings and data supports ongoing research efforts and informs future treatment strategies. This factor will accelerate the demand of the Global Pediatric Neuroblastoma Treatment Market.
Key Market Challenges
Toxicity and Long-Term Effects
The standard treatments for pediatric neuroblastoma, which often include chemotherapy, radiation therapy, and surgery, can cause severe side effects in young patients. These treatments may damage healthy tissues and organs in addition to targeting cancer cells. The toxicity can result in short-term complications, such as nausea, fatigue, and hair loss, which can significantly impact a child's quality of life during treatment. Beyond the immediate treatment period, pediatric neuroblastoma survivors may face long-term health issues and late effects of treatment. These can include developmental delays, growth problems, hormonal imbalances, organ dysfunction, and an increased risk of secondary cancers. Monitoring and managing these long-term health issues require ongoing medical care and support. The toxicity and long-term effects of treatment can affect a child's physical and emotional well-being, as well as their ability to engage in normal childhood activities. This can have a lasting impact on their quality of life and overall development. Pediatric neuroblastoma and its treatment can take a toll on the psychological well-being of both patients and their families. Coping with treatment-related toxicity and long-term effects can be emotionally challenging, requiring psychosocial support and mental health services. Pediatric neuroblastoma survivors often require specialized survivorship care to address the unique health issues that may arise years after treatment. Access to comprehensive follow-up care and support services is essential to managing these long-term effects effectively. Finding the right balance between delivering effective treatment and minimizing toxicity is a complex challenge in pediatric neuroblastoma care. Oncologists must make treatment decisions that maximize the chances of a cure while minimizing potential harm.
Late Diagnosis
Neuroblastoma is often diagnosed at an advanced stage, which makes treatment more challenging. Late diagnosis means that the cancer has had more time to spread to other parts of the body (metastasize), requiring more aggressive treatment approaches. Advanced-stage neuroblastoma may have fewer treatment options found at compared to early-stage disease. Late diagnosis may limit the effectiveness of certain treatments, potentially impacting the chances of a favorable outcome. The prognosis for pediatric neuroblastoma is significantly better when the cancer is diagnosed at an earlier stage. Late diagnosis can lead to lower survival rates and poorer long-term outcomes for affected children. Late-stage neuroblastoma often requires more intensive and aggressive treatments, such as high-dose chemotherapy, radiation therapy, and stem cell transplantation. These treatments can have more significant side effects and long-term complications. Late diagnosis can have a profound psychological and emotional impact on the child and their family. Coping with a late-stage cancer diagnosis can be extremely distressing, and families may experience heightened anxiety and emotional stress. Late diagnosis can result in delays in accessing specialized pediatric oncology care. Timely access to experienced medical teams is crucial for developing and implementing an effective treatment plan. Neuroblastoma tends to metastasize to distant sites, such as the bones, bone marrow, and other organs. Late diagnosis increases the risk of cancer cells spreading to these critical areas, making treatment more complex. Neuroblastoma can present with vague and non-specific symptoms, especially in its early stages. These symptoms, such as abdominal pain, weight loss, and fatigue, can be attributed to other common childhood illnesses, leading to delayed diagnosis.
Key Market Trends
Minimizing Radiation
Radiation therapy, while effective in treating neuroblastoma, can cause long-term side effects, especially in pediatric patients. These side effects may include growth abnormalities, developmental delays, and an increased risk of secondary cancers. Minimizing radiation aims to mitigate these risks. Innovations in radiation therapy techniques, such as intensity-modulated radiation therapy (IMRT) and proton therapy, allow for more precise targeting of cancer cells while sparing nearby healthy tissues. This precision reduces the potential for collateral damage and long-term toxicity. Radiation oncologists are increasingly tailoring treatment plans to each patient's specific needs and tumor characteristics. This individualized approach ensures that the minimum necessary radiation dose is used while maximizing therapeutic benefits. Minimizing radiation is often achieved through combination therapies. For instance, using chemotherapy or surgery to shrink tumors before radiation may allow for lower radiation doses and less toxicity. Risk stratification of neuroblastoma patients helps determine the appropriate level of treatment intensity. Low-risk patients may receive less aggressive therapy, including reduced radiation, to minimize long-term effects. Ongoing clinical trials are exploring novel treatment approaches that may reduce the reliance on radiation therapy or allow for lower radiation doses. These trials aim to maintain or improve treatment outcomes while minimizing toxicity. As more children with neuroblastoma survive into adulthood, there is a growing emphasis on long-term survivorship care. Minimizing radiation plays a role in reducing the late effects of treatment and improving the quality of life for survivors.
Segmental Insights
Treatment Type Insights
In 2022, the Global Pediatric Neuroblastoma Treatment Market largest share was held by Chemotherapy segment and is predicted to continue expanding over the coming years.
End-User Insights
In 2022, the Global Pediatric Neuroblastoma Treatment Market largest share was held by
Regional Insights
The North America region dominates the Global Pediatric Neuroblastoma Treatment Market in 2022.
Recent Developments
- In March 2022, Recordatihas successfully completed its previously announced acquisition of EUSA Pharma,a global specialty pharmaceutical company specializing in rare and nicheoncology diseases. EUSA Pharma was previously owned by funds managed by EWHealthcare Partners. EUSA Pharma boasts a strong pharmaceutical portfolioconsisting of four rare and niche oncology products. Among these products areQarziba, an anti-GD2 monoclonal antibody used for treating high-riskneuroblastoma, and Sylvant, the first and only approved treatment forIdiopathic Multicentric Castleman's disease (iMCD) in both the United Statesand Europe.
- In February 2023, The PanAmerican Health Organization (PAHO), in collaboration with St. Jude Children’sResearch Hospital and Childhood Cancer International, has initiated a newcampaign with the goal of informing parents, caregivers, and healthcareprofessionals in Latin America and the Caribbean about the initial signs of themost prevalent cancers in children and adolescents. The objective is to enhancethe early detection and treatment outcomes of these cancers. Named 'SupportKids with Cancer,' the campaign was launched in anticipation of InternationalChildhood Cancer Day, observed on February 15th. Its primary aim is to promoteawareness of common pediatric cancers such as lymphoblastic leukemia, Hodgkinlymphoma, and retinoblastoma. The campaign underscores recognizable symptoms,including fatigue, unexplained bruising, swelling or lumps, loss of appetite,persistent headaches, dizziness, vomiting, and bone pain.
Key Market Players
- UnitedTherapeutics Corporation
- APEIRON Biologics AG
- Baxter International Inc.
- Cell Ectar Biosciences Inc.
- Pfizer Inc.
- Bayer AG
- Provectus Biopharmaceuticals Inc.
- Sartorius AG
- Amgen Inc.
- F. Hoffmann-La Roche AG
| By Treatment Type | By End-User | By Region |
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy